Clinical Research of the Prognostic Influence of NSAIDS's Anti-inflammatory Effect on Senior Patients With Hip Fracture
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01583660|
Recruitment Status : Unknown
Verified April 2012 by Li Shaoguang, Beijing Army General Hospital.
Recruitment status was: Recruiting
First Posted : April 24, 2012
Last Update Posted : April 24, 2012
With the development of society, aged population is growing. Hip fracture is the most common disease for aged people. With the life being longer than before, incidence of this disease is growing. The mortality of this disease is high—— almost 10% patients will die within 1 month, about 1/3 of patients will die within 12 months. About 20%-30% aged people who have hip fracture will die within one year.
The damaged organs caused by excessive inflammatory is one of possible reasons to cause higher mortality. Therefore, the investigators imagined that if they gave medicines to patients in time to reduce the inflammatory level, the inflammatory might have less effects on organs, and the recovery could be improved.
The investigators hypothesis on the basic research: the anti-inflammatory function of non steroidal antiinflammatory drugs (NSAIDs) can inhibit the inflammatory level of elderly hip fracture, so as to improve the recovery level and reduce the complicating disease and mortality. The investigators designed a clinic study to research NSAIDS' effects on inflammatory level and prognosis of elderly hip fracture.
|Condition or disease||Intervention/treatment|
|Hip Fracture||Drug: celecoxib Drug: Acetaminophen oxycodone|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||800 participants|
|Official Title:||Clinical Research of the Prognostic Influence of NSAIDS's Anti-inflammatory Effect on Senior Patients With Hip Fracture|
|Study Start Date :||January 2012|
|Estimated Primary Completion Date :||December 2013|
|Estimated Study Completion Date :||December 2015|
- Drug: celecoxib
200mg, PO.Bid, last from admission to hospital to one week after operation.Other Name: celebrex
- Drug: Acetaminophen oxycodone
1 tablet(Acetaminophen 325mg oxycodone 5mg), Q6h orally take,last from admission to hospital to one week after operation.Other Name: Oxydodone and Acetaminophen Tablets
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01583660
|Contact: Shaoguang Li, Dr.||+email@example.com|
|Contact: Tiangsheng Sun, Dr.||+firstname.lastname@example.org|
|Beijing Army General Hospital||Recruiting|
|Beijing, Beijing, China, 100700|
|Contact: Shaoguang Li, Dr. 13488865818 email@example.com|
|Contact: Tiansheng Sun, Dr. 13501072165 firstname.lastname@example.org|
|Principal Investigator: Shaoguang Li, Dr.|
|Study Chair:||Tiangsheng Sun, Prof.||Beijing Army General Hospital|